Federico Cappuzzo mainly investigates Lung cancer, Internal medicine, Oncology, Epidermal growth factor receptor and Gefitinib. His Lung cancer study incorporates themes from Cancer, Adenocarcinoma, Prospective cohort study and Carcinoma. His research in Internal medicine tackles topics such as Surgery which are related to areas like ROS1.
His Oncology study combines topics from a wide range of disciplines, such as Immunohistochemistry, Tolerability and Survival analysis. His studies deal with areas such as Gene dosage, Cancer research and KRAS as well as Epidermal growth factor receptor. He has included themes like Endocrinology, Tyrosine kinase, Erlotinib, Tyrosine-kinase inhibitor and Growth factor receptor in his Gefitinib study.
His main research concerns Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research. Internal medicine and Surgery are frequently intertwined in his study. His work in the fields of Oncology, such as Erlotinib, intersects with other areas such as In patient.
The Lung cancer study combines topics in areas such as Epidermal growth factor receptor and Adenocarcinoma. The study incorporates disciplines such as Gastroenterology and Hazard ratio in addition to Chemotherapy. His research in Cancer research intersects with topics in Bioinformatics, Tyrosine kinase, Carcinoma, Exon and Gene dosage.
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Carboplatin and Chemotherapy. Internal medicine connects with themes related to Gastroenterology in his study. His studies in Oncology integrate themes in fields like Cancer, Disease and Maintenance therapy.
His work deals with themes such as Pembrolizumab, KRAS, Histology and Immunohistochemistry, which intersect with Lung cancer. His Carboplatin research includes elements of Atezolizumab and Paclitaxel. The various areas that Federico Cappuzzo examines in his Chemotherapy study include Dacomitinib and Drug resistance.
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Progression-free survival and Hazard ratio. His Oncology study incorporates themes from Adverse effect and Cohort. His Lung cancer research incorporates themes from Pembrolizumab and KRAS.
His Progression-free survival research is multidisciplinary, incorporating elements of Cancer research, Mutation, Point mutation, Afatinib and Performance status. The concepts of his Hazard ratio study are interwoven with issues in Carboplatin, Atezolizumab, Chemotherapy and Stage. His Carboplatin research includes themes of Maintenance therapy and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu.
The New England Journal of Medicine (2014)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi.
The New England Journal of Medicine (2018)
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo;Fred R. Hirsch;Elisa Rossi;Stefania Bartolini.
Journal of the National Cancer Institute (2005)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter.
Lancet Oncology (2010)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe.
Lancet Oncology (2015)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo;Tudor Ciuleanu;Lilia Stelmakh;Saulius Cicenas.
Lancet Oncology (2010)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George.
Nature Genetics (2012)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer.
Science Translational Medicine (2010)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard J West;Michael McCleod;Maen Hussein;Alessandro Morabito.
Lancet Oncology (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: